WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524744
CAS#: 101183-99-7
Description: CK 2289 is an inhibitor of type III cyclic 3'5'-adenosine monophosphate phosphodiesterase with potential utility in the treatment of congestive heart failure.
Hodoodo Cat#: H524744
Name: CK 2289
CAS#: 101183-99-7
Chemical Formula: C15H14N4O2
Exact Mass: 282.11
Molecular Weight: 282.300
Elemental Analysis: C, 63.82; H, 5.00; N, 19.85; O, 11.34
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CK 2289; CK-2289; CK2289.
IUPAC/Chemical Name: 2H-Imidazol-2-one, 4-ethyl-1,3-dihydro-5-(4-(1H-imidazol-1-yl)benzoyl)-
InChi Key: VQVLBYWJKODQIR-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H14N4O2/c1-2-12-13(18-15(21)17-12)14(20)10-3-5-11(6-4-10)19-8-7-16-9-19/h3-9,17-18H,2H2,1H3
SMILES Code: c1cncn1c1ccc(C(c2c([nH]c([nH]2)=O)CC)=O)cc1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 282.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Chen W, Hu XY, Lu HN. [Impacts of Biochar Input on Mineralization of Native Soil Organic Carbon]. Huan Jing Ke Xue. 2015 Jun;36(6):2300-5. Chinese. PubMed PMID: 26387339.
2: Avesani CM, Draibe SA, Kamimura MA, Cendoroglo M, Pedrosa A, Castro ML, Cuppari L. Assessment of body composition by dual energy X-ray absorptiometry, skinfold thickness and creatinine kinetics in chronic kidney disease patients. Nephrol Dial Transplant. 2004 Sep;19(9):2289-95. Epub 2004 Jul 13. PubMed PMID: 15252158.
3: Greenberg SS, Paul J, Luisi A. Pharmacological comparison of CK-2289, an inodilator agent, with milrinone and enoximone. Arch Int Pharmacodyn Ther. 1991 Jan-Feb;309:103-24. PubMed PMID: 1653560.